Advertisement
Research ArticleArticle

Activation of Nuclear Factor-κB Pathway by Simvastatin and RhoA Silencing Increases Doxorubicin Cytotoxicity in Human Colon Cancer HT29 Cells

Chiara Riganti, Sophie Doublier, Costanzo Costamagna, Elisabetta Aldieri, Gianpiero Pescarmona, Dario Ghigo and Amalia Bosia
Molecular Pharmacology August 2008, 74 (2) 476-484; DOI: https://doi.org/10.1124/mol.108.045286
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Activation of Nuclear Factor-κB Pathway by Simvastatin and RhoA Silencing Increases Doxorubicin Cytotoxicity in Human Colon Cancer HT29 Cells

Chiara Riganti, Sophie Doublier, Costanzo Costamagna, Elisabetta Aldieri, Gianpiero Pescarmona, Dario Ghigo and Amalia Bosia
Molecular Pharmacology August 1, 2008, 74 (2) 476-484; DOI: https://doi.org/10.1124/mol.108.045286
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement